ArticleThe Korean journal of pain2026
Effectiveness of ropivacaine-loaded ReproGel drug delivery system in a rat model of postoperative pain.
Article in The Korean journal of pain, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Effective postoperative pain management is challenging because of adverse effects associated with traditional analgesic methods. Multimodal analgesia, targeting multiple pain pathways, offers improved pain relief while reducing side effects. The authors evaluated the analgesic and anti-inflammatory effects of the ReproGel drug delivery system (DDS) combined with ropivacaine in a rat model of postoperative pain. Methods: Sixty-four Sprague-Dawley rats were randomly assigned to four groups: sham treatment, ReproGel DDS, ropivacaine 0.375%, and ReproGel DDS + ropivacaine 0.375%. Mechanical withdrawal threshold (MWT) tests and rotarod assessments were conducted at baseline; at 30, 60, 90, 120, 180, and 240 minutes; at 24 and 48 hours; and at 1 week postoperatively. Blood samples were collected at 24, 48 hours, and 1 week to measure levels of tumor necrosis factor-α, interleukin (IL)-1β, and IL-6 before euthanasia. Results: The ReproGel DDS + ropivacaine group demonstrated significantly higher MWT values, demonstrating enhanced analgesia from 30 to 240 minutes postoperatively. Combination treatment with ReproGel demonstrated superior effectiveness at 240 minutes, outperforming ropivacaine alone, indicating a sustained analgesic effect. IL-1β and IL-6 levels were significantly reduced in groups receiving ropivacaine, particularly in the ReproGel DDS + ropivacaine group, at 24 and 48 hours postoperatively. No motor impairment was observed, confirming the safety of ReproGel DDS + ropivacaine in preserving motor function. Conclusions: The combination of ReproGel DDS and ropivacaine 0.375% in a postoperative rat model offers prolonged analgesic and anti-inflammatory effects without motor impairment, positioning it as a safe and effective option for postoperative pain management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.